Treatment Intensification in Metastatic HSPC

CME Available: https://auau.auanet.org/node/41733

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 

2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 

3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.